NIKKEI 225
38,289.83 +87.46 (+0.23%) HANG SENG
18,306.25 -7.61 (-0.04%) CRUDE OIL
79.26 +0.27 (+0.34%) GOLD FUTURES
2,317.80 -4.50 (-0.19%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,180.74 -904.87 (-1.81%)
Equillium, Inc. (EQ)
After hours:
| Previous close | 1.7800 |
| Open | 1.8300 |
| Bid | 1.6500 x 100 |
| Ask | 1.7300 x 100 |
| Day's range | 1.6601 - 1.8300 |
| 52-week range | 0.4500 - 3.2500 |
| Volume | |
| Avg. volume | 248,257 |
| Market cap | 59.933M |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif., May 07, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Center in Chicago, Illinois, May 3 – 7.
- Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., April 03, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee appr
- Business Wire
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
LA JOLLA, Calif., April 01, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients. The data suggests high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added t
